Many studies examining and comparing the effects of disease-modifying therapies in MS were presented over the three days of the ECTRIMS 2018 conference in Berlin. Here are summaries of just some of the research presented:
- The sphingosine 1-phosphate receptor (S1PR) modulator ozanimod was found to significantly reduce the rate of relapse, including severe relapse, compared with interferon beta-1a in patients with relapsing MS. The finding followed analysis of pooled data from two phase III studies, involving 2,659 patients. (Comi G, et al. P869)